Takeda (Portugal)

Homepage: takeda.com

Alternate name: Takeda Farmacêuticos Portugal

Parent institution: Takeda (Japan)

Related institution: Takeda (Poland)

ROR: 01tzqyt58

OpenAlex ID: I4405254462

EE288 Costs Associated With Kidney Transplant in Portugal

2025 · Pedro Carvalho, Margarida Borges, et al. · Value in Health · 1

Oncologists’ preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment

2025 · Kathryn F. Mileham, Laura Panattoni, et al. · Future Oncology · 1

Oncologists’ preferences for first-line (1L) treatment of ALK-positive metastatic NSCLC in the US: A discrete choice experiment (DCE).

2025 · Kathryn Finch Mileham, Laura Panattoni, et al. · Journal of Clinical Oncology · 1

Sociodemographic, Clinical, and Therapeutic Characterization of Multiple Myeloma Patients (CharisMMa Study) with Symptomatic Relapse and/or Refractory Disease: An Observational, Multicenter Study in Portugal

2026 · Rui Bergantim, José Guilherme Freitas, et al. · Hematology Reports

PP01.46: Prescribing Patterns and Experience in First-line Treatment of ALK+ metastatic NSCLC in the United States – Findings from a Survey of Oncology Providers

2026 · Kathryn Mileham, Marlon Graf, et al. · Journal of Thoracic Oncology

HSD132 An Integral Approach to Assess the 3 Human Normal Immunoglobulin Formulations for Primary Immunodeficiency in Portugal: Combining Costs, Patient's Preferences, and HCP Choices

2024 · M Sameiro Lemos, JP Lopes da Cruz, et al. · Value in Health

HTA232 A Multi-Criteria Decision Analysis Framework for the Value Assessment of First-Line Treatment of Adult Patients with Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

2023 · P. Martins, B. Vandewalle, et al. · Value in Health

EE670 Management Costs of Grade 3/4 Adverse Events Associated with Emerging and Existing Systemic Therapies for Metastatic Colorectal Cancer with at Least Two Prior Lines of Therapy in Italy, Portugal, Spain, and the United States

2023 · V. Paly, L.G. Hernandez, et al. · Value in Health

EPH141 The Impact of Short Bowel Syndrome in Adult Patients in Portugal

2023 · M. Sameiro Lemos, M. Faria, et al. · Value in Health

RWD149 Real-Life Dose Escalation of Patients with Ulcerative Colitis and Crohn’s Disease Undergoing Biologic Treatment in Portugal

2023 · J.P. Lopes da Cruz, M. Faria, et al. · Value in Health

RWD6 Costs of Dose Escalation Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Ustekinumab in Portugal

2023 · J.P. Lopes da Cruz, M. Faria, et al. · Value in Health

POSB151 Brigatinib As a Leading Option to Manage Previously Not Treated Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer (ALK+ NSCLC) in Portugal

2022 · S Monteiro, P Labisa, et al. · Value in Health

Works count: 12

Citation count: 4